The FDA is considering additional action to improve the safe use of anemia drugs after reviewing new studies that "show more rapid tumor growth or shortened survival" in patients with certain types of cancers. The agency said it is looking into additional risk information provided by Amgen, maker of Epogen and Aranesp, and Procrit developer Johnson & Johnson.

Related Summaries